Angiotensin-Converting Enzyme: Difference between revisions

← Older edit Newer edit →

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

David Canner, Alexander Berchansky, Michal Harel, Cristina Murga

@@ Line 2: / Line 2: @@
 {{Clear}}
-[[Angiotensin-Converting Enzyme]] (ACE) is both an exopeptidase and endopeptindase first discovered by Skeggs et al. in 1956. <ref>Skeggs, L. T., Dorer, F. E., Kahn, J. R., Lentz, K. E., Levin, M. (1981) Experimental renal hypertension: the discovery of the Renin-Angiotensin system. Soffer, R. eds. Biochemical Regulation of Blood Pressure ,3-38 John Wiley & Sons, Inc. Hoboken.</ref> ACE is a zinc- and chloride-dependent metallopeptidase that is responsible for the metabolism of key biologically active peptides, namely Angiotensin I and Bradykinin. These two peptides play a critical role in maintaining appropriate blood pressure in the human body along with a host of other homeostatic circulatory functions. See [[Hypertension & Congestiv Heart Failure]].  ACE catalyzes the conversion of the decapeptide Angiostensin I to the octapeptide Angiostensin II. Due to its critical role in the Renin-Angiotensin-Aldosterone System (RAAS), ACE has been targeted by a number of pharmaceutical compounds to treat hypertension, diabetic nephropathy, and renal failure. <ref>PMID:10780101</ref>
+[[Angiotensin-Converting Enzyme]] (ACE) is both an exopeptidase and endopeptindase first discovered by Skeggs et al. in 1956. <ref>Skeggs, L. T., Dorer, F. E., Kahn, J. R., Lentz, K. E., Levin, M. (1981) Experimental renal hypertension: the discovery of the Renin-Angiotensin system. Soffer, R. eds. Biochemical Regulation of Blood Pressure ,3-38 John Wiley & Sons, Inc. Hoboken.</ref> ACE is a zinc- and chloride-dependent metallopeptidase that is responsible for the metabolism of key biologically active peptides, namely Angiotensin I and Bradykinin. These two peptides play a critical role in maintaining appropriate blood pressure in the human body along with a host of other homeostatic circulatory functions. See [[Hypertension & Congestive Heart Failure]].  ACE catalyzes the conversion of the decapeptide Angiostensin I to the octapeptide Angiostensin II. Due to its critical role in the Renin-Angiotensin-Aldosterone System (RAAS), ACE has been targeted by a number of pharmaceutical compounds to treat hypertension, diabetic nephropathy, and renal failure. <ref>PMID:10780101</ref>
 <br />